The push to cap insulin costs is back on the table, and this time it’s arriving with a familiar promise—and a slightly altered strategy.
A bipartisan group of senators is reintroducing the INSULIN Act of 2026, an effort aimed at placing a firm ceiling on what many Americans pay out of pocket for insulin. The proposal, led by Sens. Jeanne Shaheen, Susan Collins, Raphael Warnock, and John Kennedy, targets a gap left open after Congress capped insulin costs for Medicare recipients in 2022 but stopped short of extending that protection to those with private insurance or no insurance at all.
The mechanics of the bill are straightforward. Starting in 2027, group and individual health plans would be prohibited from applying deductibles to certain insulin products, and monthly costs would be capped at $35 for a 30-day supply. A year later, the structure shifts slightly—patients would pay either $35 or 25% of the drug’s negotiated price, whichever is lower.
That framework mirrors the Medicare cap but expands it into the commercial insurance market, where pricing has remained uneven and, in many cases, significantly higher.
The bill also attempts to reach beyond insured patients, which has been a sticking point in past efforts. A five-year pilot program across 10 states would extend the $35 cap to uninsured individuals, a group that often faces the highest prices and the least predictable access. Lawmakers involved in shaping the bill pointed to cases of patients rationing insulin—stretching doses or skipping them entirely—as a driving force behind that provision.
At the same time, the legislation goes after the structure behind the pricing. It includes measures aimed at pharmacy benefit managers, whose role in negotiating drug prices has drawn increasing scrutiny. It also calls for steps to encourage biosimilar competition and orders a federal study into delays that keep lower-cost insulin alternatives from reaching the market.
The political timing is not accidental. With the 2026 midterms approaching and a narrow 53-47 Senate split, the bill places pressure on both parties to show movement on prescription drug costs. Collins, one of the Republican co-sponsors, faces a potentially competitive race, while Shaheen has indicated this effort is among the priorities she hopes to see completed before leaving the Senate.
There is also overlap with President Donald Trump’s ongoing focus on drug pricing. His administration’s “Most Favored Nation” policy and related agreements with pharmaceutical companies, along with the launch of a direct-to-consumer platform listing discounted medications, have added another layer to the pricing debate. Some insulin products are already being offered at reduced rates through those channels, creating a parallel track to the legislative effort.
Still, legislation carries a different weight. A statutory cap would apply broadly and consistently, rather than relying on voluntary pricing or negotiated programs.
The challenge now is procedural. Previous versions of insulin pricing reform have stalled despite bipartisan backing, often getting caught in larger legislative battles or stripped down during negotiations. Supporters of the current bill argue that the combination of insured caps, uninsured pilots, and cost-structure reforms gives it a more complete footing than earlier attempts.
